Genomic Health, Inc. (NASDAQ:GHDX)‘s stock had its “hold” rating reaffirmed by investment analysts at Jefferies Group LLC in a research note issued on Friday. They presently have a $34.00 price target on the medical research company’s stock. Jefferies Group LLC’s price objective would suggest a potential upside of 0.83% from the stock’s current price. Jefferies Group also issued estimates for Genomic Health’s Q3 2017 earnings at ($0.01) EPS, Q1 2018 earnings at $0.07 EPS, Q2 2018 earnings at $0.07 EPS, Q3 2018 earnings at $0.07 EPS and FY2018 earnings at $0.27 EPS.

A number of other research analysts have also weighed in on GHDX. Zacks Investment Research lowered shares of Genomic Health from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Piper Jaffray Companies reaffirmed a “hold” rating and issued a $31.00 price objective on shares of Genomic Health in a research note on Thursday, August 3rd. BidaskClub lowered shares of Genomic Health from a “hold” rating to a “sell” rating in a research note on Friday, August 4th. Canaccord Genuity dropped their price objective on shares of Genomic Health from $36.00 to $35.00 and set a “buy” rating on the stock in a research note on Tuesday, August 15th. Finally, Cowen and Company reaffirmed a “hold” rating and issued a $34.00 price objective on shares of Genomic Health in a research note on Friday, September 1st. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and one has issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $32.00.

Shares of Genomic Health (NASDAQ:GHDX) traded down 0.41% during midday trading on Friday, reaching $33.72. 95,695 shares of the company’s stock traded hands. The stock’s market cap is $1.17 billion. Genomic Health has a 12 month low of $26.37 and a 12 month high of $34.02. The stock has a 50 day moving average of $31.98 and a 200-day moving average of $31.72.

Genomic Health (NASDAQ:GHDX) last released its quarterly earnings data on Tuesday, August 1st. The medical research company reported ($0.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.02). Genomic Health had a negative net margin of 1.50% and a negative return on equity of 4.33%. The business had revenue of $85.50 million during the quarter, compared to the consensus estimate of $86.08 million. During the same period last year, the business posted ($0.18) earnings per share. The firm’s quarterly revenue was up 4.3% on a year-over-year basis. On average, equities research analysts forecast that Genomic Health will post ($0.04) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another publication, it was illegally copied and reposted in violation of United States & international trademark and copyright laws. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/10/21/genomic-health-inc-ghdx-rating-reiterated-by-jefferies-group-llc.html.

In related news, COO G Bradley Cole sold 5,000 shares of the firm’s stock in a transaction dated Tuesday, October 10th. The shares were sold at an average price of $31.93, for a total transaction of $159,650.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider James J. Vaughn sold 8,000 shares of the firm’s stock in a transaction dated Tuesday, August 8th. The shares were sold at an average price of $30.59, for a total transaction of $244,720.00. The disclosure for this sale can be found here. Insiders have sold 33,000 shares of company stock worth $1,022,620 over the last three months. 46.20% of the stock is owned by insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Eagle Asset Management Inc. lifted its position in shares of Genomic Health by 18.4% during the second quarter. Eagle Asset Management Inc. now owns 379,473 shares of the medical research company’s stock valued at $12,351,000 after purchasing an additional 58,920 shares in the last quarter. American International Group Inc. lifted its position in shares of Genomic Health by 7.1% during the first quarter. American International Group Inc. now owns 11,505 shares of the medical research company’s stock valued at $362,000 after purchasing an additional 765 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of Genomic Health by 10.9% during the second quarter. Renaissance Technologies LLC now owns 813,300 shares of the medical research company’s stock valued at $26,473,000 after purchasing an additional 80,100 shares in the last quarter. Schwab Charles Investment Management Inc. lifted its position in shares of Genomic Health by 8.6% during the first quarter. Schwab Charles Investment Management Inc. now owns 482,675 shares of the medical research company’s stock valued at $15,200,000 after purchasing an additional 38,199 shares in the last quarter. Finally, Goldman Sachs Group Inc. lifted its position in shares of Genomic Health by 38.3% during the first quarter. Goldman Sachs Group Inc. now owns 294,048 shares of the medical research company’s stock valued at $9,259,000 after purchasing an additional 81,425 shares in the last quarter. 88.90% of the stock is currently owned by institutional investors.

About Genomic Health

Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

Analyst Recommendations for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.